Covaxin | Bharat Biotech
Bharat Biotech ramps up Covaxin production by 200 million doses
New Delhi/IBNS: Bharat Biotech on Thursday said it is gearing up to increase manufacturing capacity of Covaxin by 200 million doses per year.
The additional doses will take the total volume of doses to about a billion per year, the company said today in the later part of the evening, amid demands of coronavirus vaccine from various states which are still waiting to extend the vaccination drive to people in the 18-45 age group.
The vaccine manufacturer has raised the manufacturing capacity at its subsidiary's Ankleshwar-based facility in Gujarat, CHIRON BEHRIN vaccines.
"The company plans to produce 200 million doses of Covaxin per year in its GMP facilities that are already operational for the production of vaccines based on Inactivated Vero Cell Platform Technology, under stringent levels of GMP and biosafety," Bharat Biotech said.
The Ankaleshwar plant will start rolling out vaccines from the fourth quarter of the year.
The company has already increased the manufacturing capacity of its Hyderabad plant to 700 million doses per annum.
Covaxin, is an indigenously developed coronavirus vaccine, in a collaboration between Bharat Biotech, Indian Council of Medical Research and the National Institute of Virology.
The second vaccine used in India, Covishield, has been developed by Swedish drug major AstraZeneca and Oxford University, and manufactured in India by the Serum Institute.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
